Kiyatec, a Greenville, SC-based functional precision oncology company, received an investment from The Brain Tumor Investment Fund, and Sontag Innovation Fund.
The amount of the deal was not disclosed.
The company intends to use the funds to support further commercialization and adoption of its clinically validated testing platform, 3D-Predict.
Led by CEO Matt Gevaert, Kiyatec is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. Its Clinical Services offer clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, non-small cell lung cancers, and rare tumors in its CLIA certified lab. The Drug Development Services work in partnership with biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across the majority of solid tumor types.
FinSMEs
18/05/2023